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Abstract
Using selective bi-directional breeding procedures, two different lines of mice were developed.
The NC900 line is highly reactive and attacks their social partners without provocation, whereas
aggression in NC100 animals is uncommon in social environments. The enhanced reactivity of
NC900 mice suggests that emotionality may have been selected with aggression. As certain forms
of anxiety promote exaggerated defensive responses, we tested NC900 mice for the presence of an
anxiety-like phenotype. In the open field, light-dark exploration, and zero maze tests, NC900 mice
displayed anxiety-like responses. These animals were less responsive to the anxiolytic actions of
diazepam in the zero maze than NC100 animals; diazepam also reduced the reactivity and attack
behaviors of NC900 mice. The NC900 mice had reduced diazepam-sensitive GABAA receptor
binding in brain regions associated with aggression and anxiety. Importantly, there was a selective
reduction in levels of the GABAA receptor α2 subunit protein in NC900 frontal cortex and
amygdala; no changes in α1 or γ2 subunit proteins were observed. These findings suggest that
reductions in the α2 subunit protein in selected brain regions may underlie the anxiety and
aggressive phenotype of NC900 mice. Since anxiety and aggression are comorbid in certain
psychiatric conditions, such as borderline personality and posttraumatic stress disorder,
investigations with NC900 mice may provide new insights into basic mechanisms that underlie
these and related psychiatric conditions.
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1. Introduction
Currently, diagnoses of psychiatric disorders are made according to phenomenologic criteria
[1] and the biologic bases of conditions are inferred from pharmacological actions of
therapeutic drugs. As this approach is limited, some researchers have turned to using gain-
or loss-of-function mutants to develop animal models where certain symptoms of psychiatric
conditions are recapitulated [14]. Alternatively, selective breeding strategies have been
employed to develop lines of mice that have a high propensity to display certain
endophenotypes [31]. Using the latter approach, the North Carolina (NC) lines of mice were
developed [16,27]. NC900 mice are highly reactive and readily attack their social partners,
whereas NC100 animals rarely attack and show non-agonistic approach behaviors and
immobility in social situations. In rodents, attack behaviors are elicited in response to
unavoidable contact with a proximal threatening stimulus, while immobility appears in
response to distal threat to avoid detection [23]. Since attack behaviors potentially reflect a
higher state of acute emotional response, NC900 attack behaviors may reflect higher
baseline levels of emotionality, such as anxiety.
In humans, anxiety disorders are not commonly associated with aggression [1]. However,
relationships between anxiety and aggression in borderline personality [36,60] and
posttraumatic stress disorder are well-known [5,6,40]. Interestingly, some patients diagnosed
with anxiety disorders display atypical responses to benzodiazepines [47,53,54] and exhibit
attenuated benzodiazepine-sensitive GABAA receptor binding [12,13,38,62] . Due to these
relationships, we have hypothesized that social reactivity and aggression in NC900 mice
may reflect heightened anxiety and this may be associated with altered GABAergic function.
Hence, the purpose of the present studies was to determine whether alterations in
GABAergic function can be attributed to the increased aggression in the NC900 mice.
2. Materials and methods
2.1. Animals
NC100 and NC900 males (58-85 days of age) were obtained from the 44-46th generations of
selective breeding [16] at the University of North Carolina and Duke University. Briefly,
NC100 and NC900 lines were derived from ICR mice. NC900 males that attacked most
rapidly and frequently in the dyadic test were bred; NC100 males that failed to attack and
showed freezing were used for breeding. Females within the same line whose male siblings
had been selected were bred with non-related males. Once pregnant, females were
individually housed until their pups were weaned at 21 days of age. Male C3H/HeJ mice
(Jackson Laboratories, Bar Harbor ME) were used as test partners in the dyadic test [29,50].
As retinal degeneration can occur in this strain of mice, their visual acuity was assessed 24 h
before social testing [50]. Animals were housed (cage size: 29.2 × 18 × 12 cm) normally
3-4/cage or at only 1/cage for the dyadic test, and maintained under a 14:10 h light-dark
cycle (lights on at 0700 h) and were given rodent chow and water ad libitum. All
experiments were conducted in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and with approved animal protocols from the University of North
Carolina and the Duke University Medical Center.
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The NC100 and NC900 mice were age-matched when testing began. All mice were first
tested in the zero maze, given a 7-10 day hiatus, then evaluated in the light-dark box or open
field before being housed in isolation for at least 2 weeks prior to administering the social
dyadic test. The mylorelaxant test was conducted in a separate set of mice that were
approximately 10 weeks of age.
Activity was measured by photocells over 5 min in the open field (21 × 21 × 30 cm) and
analyzed using the VersaMax program (AccuScan Instruments, Columbus, OH) under ~350
lux [46]. Besides overall horizontal activity, activities in the center (10 × 10 cm) and
peripheral zones were examined. The light-dark exploration apparatus consisted of a mouse
shuttle-box (MedAssociates, St. Albans, VT) with darkened (~5 lux) and lighted chambers
(~600 lux) [26]. Mice were placed on the darkened-side, 5 sec later the door to the adjoining
chamber was opened, and mice were given free access to the entire apparatus for 5 min. The
latency to first enter the lighted side (i.e., 4 paws), time spent on each side, number of
transitions between chambers, and activity (photocells) were determined by MedAssociates
software. The zero maze test was administered as outlined [46]. Mice were placed into a
closed area and given free access to the entire maze for 5 min. Behavior was scored
according to the percent of time in the open areas, latency to enter the open areas, and total
numbers of transitions from one closed area to an open area to another closed area. The open
field, light-dark exploration, and zero maze tests were conducted in an empty room between
1200-1800 h. Behaviors for the zero maze were videotaped in the absence of the investigator
and analyzed using the Observer program (Noldus Information Technologies, Leesburg,
VA).
Male NC mice were isolate-housed for 2 wks before the social dyadic test. Subsequently,
NC animals were evaluated against an unfamiliar group-housed age- and weight-matched
C3H male in a novel environment. All testing was performed under red-light illumination
(<5 lux), 1-4 h following onset of the dark cycle [50] in cages (48.3 26.8 × 20.3 cm;
Allentown Caging, Allentown, NJ) that had been cleaned prior to or between each test with
HI-CON 256 NPD detergent (CANI, Inc., Lansdale, PA) and dried. Clean irradiated 1/8”
cob bedding (Andersen Inc., Maumee, OH) was placed into the cage before testing. Mice
were placed at opposite ends of the neutral cage and separated by a solid partition. After 5
min of acclimatization, the barrier was removed and animals were permitted to interact
freely. Tests were terminated after 5 min of social interaction or if one of the mice initiated
continuous attack for 30 sec. All tests were video-taped and coded by trained observers
using the Observer program. Agreement between and within observers for all behaviors was
assessed simultaneously using Cohen’s κ [3]; in all cases κ>0.936. Twenty-four behaviors
were coded and organized into seven behavioral domains: immobility, mild social
investigation (MSI), intensive social investigation (ISI), stationary reactivity (SR),
locomotor reactivity (LR), threatening postures (TP), and attacks (see Supplementary Table
S1) [50]. Since the occurrence of a single TP or attack will change the way in which social
partners respond to one another [27,29,50], MSI, SR and LR were examined prior to the first
agonistic exchange and these behaviors were expressed as percent time prior to the first
agonistic exchange. TP and attacks were presented as the percent time relevant to the entire
test.
2.3. Diazepam treatment
Diazepam (DZ; Sigma-Aldrich, St. Louis, MO) or vehicle (saline - 0.03% Tween-80
solution) was given (i.p.) 30 min prior to behavioral testing. Parenthetically, DZ was used to
pharmacologically confirm that the anxiety-like behaviors of NC900 mice would respond to
an anxiolytic drug. The doses that were selected have been reported to be effective in the
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zero maze [46]; the doses chosen for the dyadic test do not produce myorelaxant effects in
the wire-hang test for NC900 mice. We used the open field, light-dark box, and zero maze to
demonstrate across tests that the NC900 mice display an anxiety-like phenotype. All three
behavioral tests rely upon avoidance of an anxiogenic area (i.e., center zone, lighted area,
open areas) as an index of anxiety-like behavior. We selected the zero maze because it is
very sensitive to anxiolytic treatment [46]. In the zero maze NC100 and NC900 mice were
administered vehicle, or 0.0625, 0.125, 0.250, or 0.5 mg/kg DZ. In the rotorod and wire-
hang tests, mice were pre-trained for 2 days [55]. Each session lasted 2 min on the rotorod
(16 rpm) and 20 s on the horizontal wire, separated by ~1 min. On each day mice were given
mock vehicle injections 30 min before testing. On day 3 mice were injected with vehicle or
1, 2, 5, or 10 mg/kg DZ and evaluated 30 min later in both tests. Latencies to fall from the
rotorod, grasp the horizontal wire with a rear paw, and fall from the wire were recorded.
Mice that failed to fall from the rotorod within 60 s were assigned that latency. Likewise,
mice that did not grasp the wire or fell within 10 s were assigned that score. In the contact
righting test, mice were given vehicle, 0.1, 1, 3, or 10 mg/kg DZ (i.p.) and tested 30 min
later. The mouse was placed on its feet in a plastic tube (5 cm in diameter x 22 cm long) and
the tube was rapidly rotated 180° for three consecutive trials [52]. The response was scored
as: −6 for failure to right, −5 for >5s delay in righting, −4 for >2s delay in righting, − 3 for
>1s delay in righting, −2 for righting from back < 1s, −1 for immediately rolling to the side
and righting within 1s, and 0 for no delay in righting. In the dyadic test, only NC900 mice
were administered 0.5, 1.0, or 1.5 mg/kg DZ; NC100 mice were not given DZ because they
were not aggressive; C3H test partners were not administered any drugs.
2.4. Chromatography of DZ and metabolites
Six naïve adult, males/line were given vehicle or 3 mg/kg DZ (i.p.) and euthanized by
cervical dislocation and decapitation 30 min after injection. Trunk blood was collected into
0.1 M EDTA-treated tubes and centrifuged at 8,000 x g for 10 min at 4°C. Plasma was
transferred to 0.1 M EDTA-treated tubes and stored at −80°C. Samples from vehicle-treated
mice were spiked with 100, 250, 500, or 1000 ng/ml DZ, N-desmethyldiazepam (DDP),
oxazapam (OXP), and temazepam (TMP; Sigma-Aldrich) to establish standard curves.
Blank (vehicle-treated), spiked, and samples from DZ-treated mice were acidified with
phosphoric acid, vortexed, cooled on ice for 10 min, and centrifuged at 8,000 rpm for 20
min at 4°C. Supernatants were loaded onto Waters Oasis MCX cartridges (Belmont, MA),
washed sequentially with 0.1 N HCl, 100% methanol (MeOH), and 5% NH4OH - 25%
MeOH, and eluted with 5% NH4OH - 95% MeOH. Samples were lyophilized, reconstituted
in mobile phase [20 mM phosphate buffer (pH 7.0) in 66% MeOH], sonicated, and filtered
through 0.22 μm Ultrafree-MC™ microfilters (Millipore Corporation, Bedford, MA) by
centrifugation at 4,000 x g for 2 min at room temperature (RT). Isocratic separations were
achieved at 1.2 ml/min at RT on a 0.46 × 250 mm 5 μm 238DE C18 Vydac column (The
Separations Group, Hisperia, CA), while absorbance was monitored at 232 nm.
2.5. Autoradiography of DZ binding sites in brain
Adult naïve NC100 and NC900 males were euthanized as described above and whole brains
were frozen in dry-ice cooled with N-methylbutane. Twenty μm coronal or sagittal sections
were vacuum-dehydrated at 4°C for 1 h. Slides were pre-incubated 2× 10 min at 4°C in 50
mM Tris-HCl - 120 mM NaCl buffer (pH 7.4) with 10 nM [3H]Ro15-4513 (Perkin Elmer,
Boston, MA) for 60 min at 4°C to determine total GABAA receptor binding [see 33]. DZ-
insensitive receptors were determined when 100 μM DZ was included in the incubation
buffer. Slides were washed 2x for 30 sec at 4°C in 50 mM Tris-HCl (pH 7.4), rinsed with
water for 10 sec at 4°C, air-dried at RT, and exposed to Kodak Biomax MR film (Rochester,
NY) at 4°C for 7 wks. Tritium standards (American Radiolabeled Chemicals, St. Louis,
MO) with known radioactivity levels were exposed simultaneously with brain sections and
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used for calibration curves. DZ-sensitive binding was determined by subtracting it from total
GABAA receptor binding. Binding densities were quantified using Scion image software
(version 1.63; Frederick, Maryland) and averaged from 3 brain sections/mouse. The mouse
brain stereotaxic atlas of Paxinos and Franklin [45] was used as a guide to identify the brain
regions of Ro15-4513 binding.
2.6. Western blot of benzodiazepine receptor subunit proteins
Brains from naïve NC100 and NC900 mice were removed as described above and 300 μm
coronal cryosections were taken from +3.20 to −2.30 bregma [45]. Micropunches (0.5 mm
and 1 mm diameter) from amygdala and frontal cortex were pooled separately from
respective NC100 and NC900 mice to obtain sufficient protein. Punches were sonicated in
ice-cold 10 mM HEPES, 350 mM sucrose, 5 mM EDTA buffer (pH 7.4) containing
Complete™ Protease Inhibitor Cocktail (Roche, Indianapolis, IN). Homogenates were
centrifuged at 2,000 x g for 10 min at 4°C. Supernatants were centrifuged at 100,000 x g for
30 min at 4°C and the pellet was re-suspended in homogenization buffer; an aliquot was
taken for protein assay [11]. Proteins were separated on NuPAGE™ 4-12% gels (Invitrogen,
Carlsbad, CA) and transferred to 0.45 μM Immobilon-P PVDF membranes (Millipore,
Billerica, MA). Membranes were washed 2x for 10 min in 20 mM Tris - 137 mM NaCl -
0.1% Tween-20 (TBS-T) buffer (pH 7.6) and blocked in the same buffer using 5% nonfat
dry milk (TBS-T NFM) at RT for 1 h. Blots were incubated in TBS-T NFM with α1, α2, or
γ2 subunit antisera (Alomone Labs, Jerusalem, Israel) at 1:750, 1:1000, and 1:1000
dilutions, respectively, for 1 h at RT. Following washing in TBS-T, blots were incubated in
TBS-T NFM with horseradish peroxidase-linked anti-rabbit antiserum (1:10,000 dilution;
Cell Signaling, Beverly, MA) for 1 h at RT. The blots were developed using ECL-Plus
reagents (Amersham, Piscataway, NJ), visualized by a STORM 860 imager (Amersham),
and quantified using the ImageQuant program (Amersham). Blots were stripped in 100 mM
2-mercaptoethanol, 2% SDS, and 62.5 mM Tris-HCl buffer (pH 6.7), incubated at 50°C for
30 min, washed 2× 10 min in TBS-T, and processed using β-actin antiserum (1:500 dilution;
AbCam, Cambridge, MA). The protein subunit density values were expressed relative to that
for β-actin. As negative controls, 1 μg of each subunit antiserum was pre-absorbed with 10
μg of each respective antigenic peptide (Alamone).
2.7. RT-PCR analyses of expression of the α2 subunit of the benzodiazepine receptor
Naïve mice were used in this experiment. Total RNA from NC100 and NC900 frontal cortex
was prepared using TRI Reagent® RNA Isolation Reagent (Sigma). RNA was reverse
transcribed and amplified by real-time PCR using Platinum® SYBR® Green qPCR
SuperMix-UDG (Invitrogen). GABAA receptor α2 subunit cDNA was amplified with
specific primers encompassing 5′ (Forward: 5′-ACA TGC AAT GTA TGG TCT CTG CTG
C; Reverse: 5′-TGT CTC CCA GTC CTG GTC TAA GC) and 3′ regions (Forward: 5′-
TGA GGC TTA CAG TCC AAG CCG AAT G; Reverse: 5′-ATT TAA CCT GGA GCC
ATC GGG AGC), respectively. The sample was denatured at 95°C for 3 min followed by 40
cycles of amplification at 95°C for 2s, 60°C for 20s, and 72°C for 30s. Gene expression was
normalized to GAPDH (Forward: 5′-ATG CCA TCA CTG CCA C(C/T)C AGA AG;
Reverse: 5′-TGC CAG TGA GCT TCC CGT TCA G). The full-length α2 subunit RT-PCR
product was amplified and sequenced at the Duke Sequencing Facility.
2.8. Statistics
The data are presented as means and standard errors of the mean using the Statistical
Package for the Social Sciences 11 (Chicago, IL). Line differences in the open field, light-
dark exploration, zero maze, dyadic social tests, HPLC analysis, and DZ-sensitive GABAA
receptor binding were evaluated by Student’s t-tests. Univariate ANOVA was used to
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analyze drug responses in the zero maze, wire hang, rotorod, righting reflex, and dyadic
social test. Post-hoc tests were by performed by Bonferroni corrected pair-wise
comparisons. The percent animals completing the wire-hang test was determined by χ2
tests. A p < 0.05 was considered significant.
3. RESULTS
3.1. NC900 mice display anxiety-like behaviors
In the open field, decreased activity in the center zone or increased thigmotaxis are
considered as indices of anxiety in rodents [63,64]. Overall locomotor activities for NC100
(312 ±40.5 cm) and NC900 mice (314 ±23.9 cm) were indistinguishable. By comparison,
NC900 animals spent less time in the center zone [NC100 = 131 ±21.4, NC900 = 68 ±17.6
sec; t1,17 = 2.302, p < 0.035] and engaged in more thigmotaxis [NC100 = 159 ±18.2, NC900
= 233 ±17.6 cm; t1,17 = 2.316, p < 0.039] than NC100 mice. In the light-dark exploration
test, mice displaying anxiety-like behavior tend to avoid brightly lit environments [17].
NC900 mice spent less time on the lighted side [NC100 = 45 ±9.3, NC900 = 17 ±7.1 sec;
t1,21 = 2.342, p<0.029], took longer to cross into this chamber [NC100 = 31 ±7.9, NC900
253 ±27.6 sec; t1,21 = 8.036, p<0.001], and crossed less frequently into the lighted side than
NC100 animals [NC100 = 7.5 ±1.6, NC900 = 2.3 ±1.2 times; t1,21 = 2.397, p<0.026]. In the
zero maze, a reduction in percent of time in the open areas is an index of anxiety-like
behavior [58]. NC900 mice spent less time in open areas [NC100 = 9.7 ±2.1%, NC900 = 4.1
±1.5%; t1,16 = 2.160, p<0.050], took more time to enter the open areas [NC100 = 86 ±33.3,
NC900 = 209 ±34.4 sec; t1,16 = 2.568, p<0.021], and engaged in fewer closed to open to
closed area transitions than NC100 animals [NC100 = 1.8 ±0.7, NC900 = 0.0 ±0.0
transitions; t1,16 = 2.399, p<0.029]. Since NC900 mice spent less time in the center zone and
showed enhanced thigmotaxis in the open field, avoided the lighted chamber in light-dark
box, and spent less time in the open areas of the zero maze, the present results suggest the
NC900 animals may display anxiety-like behaviors.
3.2. NC900 mice are less responsive to DZ than NC100 animals
Since NC900 mice appear to exhibit anxiety-like behaviors, animals were administered DZ
to determine whether this anxiolytic drug would alleviate these behaviors in the zero maze.
The ANOVA for percent time in the open areas failed to reveal significant main effects of
mouse line [F1,77 = 0.247, p=0.621]; however, effects of treatment [F4,77 = 3.046, p<0.022]
and the mouse line by treatment interaction [F4,77 = 22.395, p<0.001] were significant (Fig.
1A). Bonferroni corrected pair-wise comparisons showed that vehicle-treated NC900 mice
spent less time in the open areas than NC100 animals (p<0.048). The 0.0625 mg/kg dose of
DZ dramatically increased open area time for NC100 mice relative to their vehicle controls
(p<0.001), whereas this dose was ineffective in NC900 animals. Although 0.125, 0.25, and
0.5 mg/kg DZ did not alter open area time in NC100 animals relative to vehicle, the two
highest doses increased open area times in NC900 animals compared to their vehicle control
(ps<0.008) and to similarly-treated NC100 mice (ps<0.001). Hence, DZ increased open area
time in both mouse lines, but higher doses of DZ were required to alleviate the anxiety-like
responses in NC900 animals.
An examination of latency to enter the open area of the zero maze revealed a similar effect
(Fig. 1B). ANOVA failed to find significant effects of mouse line [F1,77 = 0.516, p=0.475],
but significant treatment effects [F4,77 = 4.756, p<0.002] and a significant mouse line by
treatment interaction emerged [F4,77 = 13.772, p<0.001]. Bonferroni comparisons
demonstrated that vehicle-treated NC900 mice entered the open areas more slowly than
NC100 animals (p<0.001). Although the latency to enter the open areas by NC100 mice was
the lowest with 0.125 mg/kg DZ, it was not significantly different from vehicle. By contrast,
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the latency for NC100 animals to enter the open areas was increased with 0.25 mg/kg DZ
(p<0.025). In NC900 mice, 0.125, 0.25, and 0.5 mg/kg DZ reduced the latency to enter the
open areas relative to their vehicle control (ps<0.002). At 0.25 and 0.5 mg/kg DZ, NC900
mice entered the open areas more quickly than NC100 animals given the same doses
(ps<0.050).
The numbers of transitions from closed to open to closed areas in the zero maze were
evaluated (Fig. 1C). ANOVA only revealed a significant mouse line by treatment interaction
[F4,77 = 7.029, p<0.001]. Bonferroni tests observed vehicle-treated NC900 mice made fewer
transitions than NC100 animals (p<0.005). Although transitions with NC100 mice were
decreased with 0.25 and 0.5 mg/kg DZ, these values were not significantly different from
their vehicle control. This suggests transitions are at a maximum for NC100 mice as motor
performance may be affected at higher doses (see motor performance results below). By
comparison, 0.5 mg/kg DZ enhanced transitions in NC900 animals relative to the vehicle
(p<0.001). This dose of DZ was sufficient to increase transitions of NC900 mice to levels of
the NC100 vehicle-treated animals.
To determine whether the NC900 line had a more widespread deficiency in DZ responses,
animals were evaluated for myorelaxant and motor-impairing effects of the drug. For latency
to grasp the horizontal wire (Fig. 2A), ANOVA demonstrated main effects of mouse line
[F1,100 = 31.427, p<0.001] and treatment [F4,100 = 66.220, p<0.001], and a significant
mouse line by treatment interaction [F4,100 = 6.442, p<0.001]. Bonferroni comparisons
found vehicle-treated NC100 and NC900 mice had similar latencies to grasp the horizontal
wire. For all doses of DZ, NC100 animals took longer to reach and grasp the wire than their
vehicle controls (ps<0.001). Although the latency to grasp was shorter with 1 than with 10
mg/kg DZ for NC100 mice (p<0.017), no differences were discerned among the other doses.
NC900 mice given 2, 5, or 10 mg/kg DZ took longer to grasp the wire relative to their
vehicle controls (ps<0.001).
The duration of wire hang was also examined (Fig. 2B). ANOVA showed significant effects
of mouse-line [F1,100 = 20.713, p<0.001], treatment [F4,100 = 24.637, p<0.001], and a
significant line by treatment interaction [F4,100 = 3.134, p<0.018]. Bonferroni tests noted
that durations of wire hanging for vehicle-treated NC100 and NC900 mice were similar. For
NC100 animals, all doses of DZ reduced wire hanging relative to their vehicle controls
(ps<0.012) and mice given 5 and 10 mg/kg DZ remained on the horizontal wire for less time
than animals administered 1 or 2 mg/kg DZ (ps<0.025). By contrast, only NC900 animals
given 10 mg/kg DZ had shorter wire-hang times than their vehicle controls (p<0.002).
Interestingly, wire-hang durations were longer for NC900 animals compared to NC100
animals at all doses of DZ examined (ps<0.043). Hence, NC900 animals were less
responsive to the myorelaxant effects of DZ than NC100 mice.
To examine motor-impairing effects of DZ, animals were tested on the rotorod (Fig. 2C).
ANOVA revealed significant effects of mouse line [F1,100 = 4.809, p<0.031] and treatment
[F4,100 = 75.481, p<0.001]; no significant mouse line by treatment interaction was noted.
Responses of vehicle-treated NC100 or NC900 mice were similar. Bonferroni tests reported
that both NC100 and NC900 animals showed significant dose-dependent reductions in
latencies to fall relative to their vehicle controls (ps<0.039), with the shortest latencies
occurring with the highest doses. Thus, rotorod performance was not distinguished by
mouse line.
In the contact righting reflex test (Fig. 2D), an ANOVA found mouse-line [F1,92 = 35.280,
p<0.001], treatment [F4,92 = 28.661, p<0.001], and the mouse-line by treatment interaction
to be significant [F4,92 = 4.915, p<0.001]. NC100 mice responded to all 4 doses of DZ
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(ps<0.034), whereas NC900 animals only responded to the two highest doses (ps<0.017).
NC900 mice were less responsive to the motor impairing effects of DZ than NC100 animals
(p<0.001) and these effects were evident at all doses of DZ (ps<0.038). Collectively, these
findings show that while both mouse lines respond to DZ, the NC900 mice are generally less
responsive to the anxiolytic, myorelaxant, and motor-impairing effects of the drug than
NC100 animals.
3.4. Metabolism of DZ is similar in NC100 and NC900 mice
One reason why the NC900 animals show reduced responses to DZ may be because they
may metabolize the drug more rapidly than NC100 mice. DZ and its metabolites were
examined 30 min after injection, the same time that all behaviors were assessed after DZ
administration. As expected, no DZ or metabolites were detected in the vehicle controls.
Levels of DDP (395 ±117.2 and 619 ±255.8 ng/ml) and OXP (413 ±74.8 and 313 ±51.0 ng/
ml) were not significantly different between the respective NC100 and NC900 lines; levels
of TMP were undetectable. These data indicate that the differential behavioral responses of
NC100 and NC900 mice to DZ may not be attributed to alterations in DZ metabolism.
3.5. DZ-sensitive binding is reduced in NC900 mice
An alternative explanation for the reduced sensitivity of NC900 animals to DZ may be due
to a reduction in the numbers of DZ-sensitive GABAA receptors. As there was no detectable
DZ-insensitive binding outside the cerebellum (data not shown), total [3H]Ro15-4513
binding was considered to reflect DZ-sensitive binding (Fig. 3). Binding in the frontal cortex
[t1,10 = 2.690, p<0.023], mitral layer of the olfactory bulb [t1,10 = 6.155, p<0.001], lateral
amygdala [t1,10 = 2.795, ps<0.019], ventromedial hypothalamus [t1,10 = 2.947, p<0.015],
CA1 [t1,10 = 4.110, ps<0.002] and CA3 hippocampus [t1,10 = 2.449, p<0.034], dentate gyrus
[t1,10 = 5.660, ps<0.001], basolateral amygdala [t1,10 = 3.872, p<0.003], periaqueductal gray
[t1,10 = 5.293, p<0.001], and posterior cortical amygdala [t1,9 = 3.543, p<0.006] were
significantly reduced in the NC900 compared to the NC100 males.
3.6. GABAA receptor α2 subunit protein levels are reduced in NC900 mice
The decrease in DZ-sensitive binding in NC900 mice may be due to a reduction in protein
levels of one or more subunits that comprise the benzodiazepine receptor. Since there is
considerable evidence that benzodiazepine receptor binding occurs at the interface of the α
and γ2 subunits [8] and because the α1 and α2 subunits are critical for specific DZ
responses [37,55], levels of α1, α2, and γ2 GABAA receptor subunit proteins were
examined. As NC900 mice display anxiety-like behaviors and because they have decreased
DZ binding in brain areas associated with anxiety, levels of subunit proteins were quantified
by Western blot in the frontal cortex and amygdala. The α1, α2, and γ2 subunits and β-actin
immunopositive bands were detected at approximately 49, 59, 49, and 43 kDa, respectively
(Fig. 4A). Although no appreciable line differences were observed in levels of α1 (Fig. 4B,
middle) or γ2 subunit proteins (Fig. 4B, bottom) or β-actin, concentrations of the α2 subunit
protein in NC900 mice were reduced by 31 ±4% in frontal cortex and by 40 ±7% in
amygdala compared to levels in the same brain regions from NC100 animals (Fig. 4B, top).
Selective reductions in the α2 subunit protein, but not the α1 or γ2 subunit proteins, are
consistent with decreased DZ-binding in NC900 animals, as well as, their reduced
behavioral responses to the drug.
Since the α2 subunit protein was reduced in NC900 mice, quantitative RT-PCR with
oligonucleotides encompassing the N-terminal and C-terminal coding regions of the α2
subunit mRNA were used to determine whether mRNA levels were also decreased in these
mice. After normalizing to GAPDH mRNA, no significant differences were detected
between NC100 and NC900 mice in expression of portions of the α2 subunit mRNA that
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encode the N-terminal (100 ±0.17 versus 98.33 ±0.50 units) or C-terminal (100 ±1.00 versus
99.17 ±1.25 units) regions of the protein. Sequencing the full-length mRNA transcripts also
failed to detect any polymorphisms between mouse lines (data not shown). Differential
results for quantification of the α2 subunit mRNA and protein suggest that post-translational
events that control α2 subunit protein levels are different between NC100 and NC900 mice.
3.7. Aggression in NC900 mice is reduced by DZ
As anticipated, NC100 mice showed immobility in the dyadic social test when investigated
by its C3H partner and the latency to engage in this behavior was relatively rapid, occurring
within the first min of testing (Table 1). By contrast, NC900 mice rarely displayed this
response during dyadic testing. When paired with C3H partner animals, analyses of
behaviors by NC100 and NC900 mice revealed the anticipated line differences in social
interaction (Fig. 5) that have been previously reported in the literature [16,27-29]. In the
present studies, we report for the first time, the behaviors of the C3H partner animals
towards the NC100 or NC900 target mice during the dyadic test. Although C3H social
partners rarely initiated attacks towards target mice, analyses of their behavioral responses
juxtaposed to those of the NC100 or NC900 targets provides a more complete analysis of
social behaviors in the dyadic test and they help to show whether the NC900 mice are
initiating offensive or defensive responses.
For vehicle-treated mice, two-way ANOVA were conducted to examine the effects of
mouse-line (i.e., NC100 and NC900) and mouse-type (i.e., target and partner) for each
behavioral domain. The latencies to engage in MSI and ISI were prolonged, whereas those
for SR, LR, TP, and attacks were decreased in NC900 males (Table 2). No line differences
were observed between the target animals and the C3H test partners for MSI (Fig. 5A, left
panel). By contrast, NC900 animals spent less time in ISI compared to NC100 males and
this line difference was reflected in the responses of the C3H partners (Fig. 5B, left panel).
ANOVA found significant main effects of mouse-line [F1,36 = 54.117, p<0.001]; however,
mouse-type or the interaction between these two main effects was not significant.
Bonferroni corrected pair-wise comparisons confirmed that NC900 mice and their C3H test
partners rarely initiated ISI towards each other compared to NC100 males and their partners
(ps<0.001). NC900 animals and their C3H partners spent more time in SR than NC100
targets and their partners (Fig. 5C, left panel). ANOVA revealed significant main effects of
mouse-line [F1,36 = 22.298, p<0.001]; mouse-type and the interaction were not significant.
Bonferroni comparisons showed that NC900 males and their test partners engaged in more
SR towards each other than NC100 mice and their partners (ps<0.001). Interestingly, only
NC900 males displayed LR (Fig. 5D, left panel). ANOVA noted significant effects of
mouse-line [F1,36 = 32.918, p<0.001] and mouse-type [F1,36 = 64.585, p<0.001], and the
line by mouse-type interaction was significant [F1,36 = 16.899, p<0.001]. Bonferroni tests
observed that NC900 males had higher rates of LR compared to NC100 males and all C3H
test partners (ps<0.002). NC900 mice also initiated more TP (Fig. 5E, left panel) and attacks
(Fig. 5F, left panel) than NC100 animals and all C3H partners. ANOVA for TP identified
significant effects for mouse-line [F1,36 = 5.874, p<0.018], mouse-type [F1,36 = 9.419,
p<0.003] and the interaction between the two main effects [F1,79 = 5.385, p<0.023].
Bonferroni corrected pair-wise comparisons demonstrated that NC900 animals executed
more TP than NC100 mice or all C3H partners (ps<0.002). ANOVA for attacks also
revealed significance main effects of mouse-line [F1,36 = 27.458, p<0.001] and mouse-type
[F1,36 = 63.097, p<0.001], and the interaction was significant [F1,36 = 27.458, p<0.001].
Bonferroni tests observed that NC900 males spent more time in attack behaviors than all
other mice (ps<0.001). In summary, the vehicle-treated NC900 mice were less likely to
engage in ISI, and were more likely to spend time in SR, LR, TP and attacks than vehicle-
treated NC100 mice and their C3H partners. Additionally, NC900 mice and their C3H
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partners spent less time in ISI and more time in SR compared to NC100 animals and their
partners. Notably, the C3H partners rarely engaged in LR, TP or attacks. Together, these
data demonstrate that NC900 males show heightened reactivity and aggression in a dyadic
social test, even when paired with a non-threatening C3H social partner.
Since only NC900 mice displayed an anxiety-like phenotype, had reductions of
benzodiazepine receptors in various brain areas related to anxiety, and were aggressive, only
these males were tested with DZ to determine whether their aggressive responses could be
attenuated or eliminated with this anxiolytic drug. The latencies to engage in immobility for
NC900 mice, we not affected by DZ treatments (Table 1). By comparison the latencies for
MSI were reduced, while those for ISI, SR, LR, TP and attacks were protracted by DZ for
NC900 males (Table 2). For the percent time spent in MSI for DZ-treated NC900 mice (Fig.
5A, right panel), ANOVA found significant main effects of mouse-type [F1,76 = 10.122,
p<0.001] and treatment [F3,76 = 14.911, p<0.001]; the mouse-type by treatment interaction
was also significant [F3,76 = 7.275, p<0.002]. Bonferroni corrected pair-wise comparisons
revealed that MSI was enhanced by 0.5 mg/kg DZ relative to the vehicle-control in NC900
males (p<0.001); no significant effects were observed with 1 or 1.5 mg/kg DZ. Contrasts
within dose showed that NC900 males given 0.5 or 1 mg/kg DZ engaged in more MSI than
their C3H partners (ps<0.017). Compared to C3H mice paired with vehicle-treated NC900
males, MSI in the partners was reduced when NC900 males were given 1 or 1.5 mg/kg DZ
(ps<0.036). For ISI (Fig. 5B, right panel), ANOVA demonstrated significant main effects of
mouse-type [F1,76 = 6.130, p<0.014] and treatment [F3,76 = 10.122, p<0.001]; the interaction
was also significant [F3,76 = 4.202, p<0.004]. Bonferroni tests observed that compared to
vehicle, only 1 and 1.5 mg/kg DZ increased ISI for NC900 males (ps<0.001). Although ISI
was similar between the target and partner mice when NC900 males were treated with
vehicle or 0.5 mg/kg DZ, NC900 males given 1 or 1.5 mg/kg DZ displayed more ISI than
their C3H partners (ps<0.047). Compared to the C3H mice paired with the NC900 vehicle-
control, the C3H males saw an increase in ISI (p<0.006) when the NC900 males were
administered 1 mg/kg DZ. For SR (Fig. 5C, right panel), ANOVA reported mouse-type
[F1,76 = 60.023, p<0.001], treatment [F3,76 = 3.954, p<0.010], and the interaction to be
significant [F3,76 = 2.959, p<0.048]. Bonferroni post-hoc comparisons revealed that all three
doses of DZ reduced SR for NC900 males relative to the vehicle control (ps<0.047). Within
treatment, 1 and 1.5 mg/kg DZ reduced SR to greater extents than the 0.5 mg/kg dose
(ps<0.036). With respect to C3H partners, SR was decreased when NC900 mice were given
1.5 mg/kg DZ compared to partners paired with the vehicle control or with targets given 0.5
or 1 mg/kg DZ (ps<0.045). Nevertheless, under all DZ treatments NC900 mice continued to
show less SR than their C3H partners (ps<0.013). For LR (Fig. 5D, right panel), ANOVA
observed the effects of mouse-type [F1,76 = 21.761, p<0.001] and treatment [F3,76 = 18.683,
p<0.001], and the interaction to be significant [F3,76 = 19.602, p<0.001]. Bonferroni
comparisons noted that all doses of DZ suppressed LR for NC900 males relative to vehicle
(ps<0.001). In this way, DZ eliminated differences in LR between NC900 males and their
partners. For TP (Fig. 5E, right panel), ANOVA revealed significant main effects of mouse-
type [F1,90 = 5.874, p<0.018] and treatment [F1,76 = 9.419, p<0.003], and the interaction
between these two main effects was significant [F3,76 = 5.383, p<0.023]. Bonferroni tests
showed relative to NC900 vehicle-controls, 1 and 1.5 mg/kg DZ increased TP (ps<0.048)
while 0.5 mg/kg DZ exerted little effect on these behaviors. Irrespective of the DZ dose
given NC900 mice, C3H partners showed less TP than NC900 targets (ps<0.012).
Nevertheless, TP was significantly enhanced in partners paired with NC900 males given 1.5
mg/kg DZ. Additionally, TP by C3H males paired with vehicle-treated NC900 mice was
increased when partners were paired when NC900 mice were given 0.5, 1, or 1.5 mg/kg DZ
(ps<0.037). With regards to attack behaviors (Fig. 5F, left panel), ANOVA demonstrated
significant main effects of mouse-type [F1,76 = 50.300, p<0.001] and the interaction between
treatment and mouse-type was significant [F3,76 = 5.485, p<0.001]. Bonferroni tests showed
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that 1 and 1.5 mg/kg DZ decreased attacks for NC900 males relative to vehicle (ps<0.001)
and the 0.5 mg/kg dose (ps<0.014). The frequencies of attacks were augmented in C3H
partners paired with NC900 mice given 1 or 1.5 mg/kg DZ compared to C3H males paired
with vehicle-treated NC900 animals (ps<0.040). Although C3H males showed significantly
fewer attacks towards the NC900 mice given vehicle or 0.5 mg/kg DZ (ps<0.001), these
differences vanished when NC900 targets were given 1 or 1.5 mg/kg DZ. It should be
emphasized that despite the ability of DZ to reduce attacks in NC900 males and to increase
attacks and TP in the C3H mice, the partner animals were never the first to initiate agonistic
responses in any of the tests. Intriguingly, because SR by C3H partners was reduced while
TP and attacks were enhanced, these findings suggest that the nature of the social interaction
between the NC900 and C3H animals was changed as a function of the NC900 males being
treated with DZ. Together, these findings show that DZ can enhance social interactions in
the NC900 males by increasing ISI and reducing reactivity; thereby, shifting aggressive
behavior to less intense threatening responses.
A more detailed analysis of the individual behaviors that compose MSI, ISI, SR, TP, and
attacks can be found in Supplementary Figures S1 and S2 and the companion ANOVA
results are reported in Supplementary Tables S2 and S3. LR is not presented as this domain
is unidimensional and is composed only of escapes or rapid departures; jump responses were
not observed in the NC100, NC900, and C3H mice. For MSI, the NC100 mice were more
likely to approach the unfamiliar C3H partner and initiate the social interaction than NC900
males (Supplementary Figs. S1A-S1B). By comparison, C3H partners paired with NC900
mice always initiated the interaction. Once the interaction began, NC900 animals engaged in
more sniffing than NC100 mice; C3H partners show similar levels of sniffing to both NC
mouse lines. Examination of ISI (Supplementary Figs. S1D-S1E) found that NC100 mice
and their partners spent similar amounts of time engaged in nosing behaviors; lower
frequencies of these responses were observed in NC900 males and their partners. Face-
grooming was less frequent than nosing in NC100 interactions, but NC100 mice still
engaged in this response more often than their C3H partners. Face-grooming was a rare
event in NC900 interactions. Sniffing the back and tail were not frequently observed in the
NC100 and NC900 social exchanges. SR, composed of boxing, holding, vocalizing, eye-
closing, and kicking behaviors, was not frequently observed in NC100 social interactions
(Supplementary Figs. S1G-S1H). By comparison, except for eye-closing, NC900
participated in all other forms of SR more frequently than NC100 mice. Interestingly, C3H
partners engaged in more boxing and holding than NC900 males, whereas these NC900
animals vocalized and kicked more often. Examination of the six behaviors comprising TP
revealed that these activities occurred almost exclusively in NC900 interactions, with the
majority of TP responses appearing as feints by NC900 males (Supplementary Figs. S2A-
S2B). The frequencies of attack responses and bites were similar in NC900 mice and were
observed solely in NC900 interactions (Supplementary Figs. S2D-S2E). Intriguingly,
vehicle-treated NC900 targets were more likely to bite their partners than attack.
Collectively, these findings suggest that NC900 males were less likely to approach an
unfamiliar mouse in a novel territory, and were more likely to initiate kicking and reactive
vocalizations towards social investigations by the C3H partner, than NC100 mice. The
agonistic responses of NC900 males primarily consisted of feints, bites, and attacks, with
bites occurring most frequently. Importantly, social responses of the C3H were shaped by
the actions of the NC900 males where their responses reflected the intensity of the social
interaction.
DZ treatment produced selective shifts among the individual behaviors that comprised MSI,
ISI, SR, TP, and attack (Supplementary Figs. S1A-S1I and S2A-S2F; Supplementary Table
S3). DZ increased approach behavior (MSI) and nosing (ISI), while it reduced social
reactivity (SR) and shifted agonistic responses from bites and attacks (attack) to feints and
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climb-grooming (TP). Interestingly, behaviors of the C3H partners were also changed as a
function of DZ treatment of NC900 males. Here, NC900 males become more approachable
by the C3H partners and were less reactive; however, attacks and bites were increased in the
partners. These changes in behavior occurred, for the most part, in a dose-dependent manner
with the individual behaviors in each domain being differentially responsive to DZ
treatments.
4. Discussion
4.1. NC900 mice display anxiety-like behaviors that are responsive to DZ
In the open field, overall locomotor activities were similar between NC100 and NC900
animals. Nonetheless, NC900 mice spent less time in the center zone and engaged in more
thigmotaxis than NC100 animals. As reduced time in the center zone or increased
locomotion in the perimeter are taken as indices of anxiety in rodents [63,64], these data
suggest that NC900 mice may possess an anxiety-like phenotype. Another test of this
behavior is the light-dark exploration test where anxious mice avoid brightly lit
environments [17]. Since the latencies to enter the lighted chamber and numbers of crosses
into this chamber were prolonged while times spent in the lighted side were reduced in
NC900 mice, these findings support the idea that NC900 mice present with an anxiety-like
phenotype. Finally, animals were tested in the zero maze where reduced time in the open
areas is indicative of anxiety [58]. NC900 mice not only spent reduced time in the open
areas, but they also took longer to enter the open areas and engaged in fewer transitions than
NC100 animals. In a separate investigation using the plus maze, line differences in anxiety-
like responses were not evident and were attributed to hyperactivity in the maze [32]. This
feature is a well-known limitation of the plus maze and does not confound zero maze tests
[58]. Collectively, our findings provide high face validity for anxiety-like behaviors and
suggest these responses are a stable characteristic of NC900 mice [see 25].
In the present studies, anxiety-like behaviors were pharmacologically validated with DZ in
the zero maze. Although NC100 and NC900 mice were both responsive to the anxiolytic
effects of DZ, their responses were somewhat different. NC100 mice initially spend more
time in the open areas of the maze, but as the dose increases they spend less time in these
zones because they are engaging in inactivity. By comparison, open area time is enhanced
for NC900 mice as the dose increases. Similarly, the latency to enter the open areas becomes
protracted with increasing dose for NC100 mice, whereas it is reduced for NC900 animals.
The numbers of transitions decline for NC100 mice as the dose is increased, while they are
increased for NC900 males. Parenthetically, these results are all consistent with the fact that
DZ has somewhat sedating effects in NC100 mice as is seen in the wire hang experiment. In
the zero maze the dose-dependency of the response was shifted to the right for NC900
animals. Interestingly, a similar shift in decreased benzodiazepine sensitivity is seen in some
patients diagnosed with anxiety disorder [45,53,54]. Additionally, treatment-resistant
anxiety disorder is associated with diminished GABAA receptor binding in the frontal cortex
[34,43]. Hence, the relative decreased response of NC900 mice to the anxiolytic actions of
DZ may be due to reduced GABAergic inhibition in brain regions controlling anxiety-like
behaviors.
4.2. NC900 mice show a general reduction in response to DZ
To determine whether reduced responses to DZ in the zero maze were generalized in NC900
animals, additional behaviors were evaluated. No mouse-line differences were observed
under vehicle conditions in the wire-hang, rotorod, or contact righting tests, suggesting that
neither line was impaired under basal conditions. Although NC900 mice were significantly
less responsive to DZ in the wire-hang and contact righting tests than NC100 animals,
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rotorod performance was not distinguished by mouse line. These findings are consistent with
various studies showing that effects of DZ are mediated by different GABAA receptor
mechanisms [see 18,37,55,56]. The receptor regulates anxiolytic effects of DZ in limbic
areas, whereas mylorelaxant and sedative effects are controlled by motor neurons and the
superficial layer of the dorsal horn [18,56]. It should be emphasized that the anxiolytic and
myorelaxant effects of DZ seem to be mediated by the α2 subunit protein [37], while motor
impairing effects are regulated through the α1 [55] and, at higher doses, the α3 subunit
protein [18]. Thus, NC900 debilities in the zero maze, wire hang, and contact righting tests
are consistent with a selective diminution of the α2 subunit protein within the GABAA
receptor complex.
4.3. NC900 mice have reduced DZ binding in brain
One reason why NC900 mice are less responsive to DZ may be due to differences in DZ
metabolism and/or altered expression of these receptors. Normally, DZ is rapidly
metabolized to DDP, DDP is converted to TMP and finally to OXP, or directly to OXP [61].
While formation of TMP from DDP occurs to some extent in all species, DDP conversion to
OXP is the major pathway in rodents. As HPLC analyses failed to demonstrate line
differences in DZ metabolism, the differential behavioral responses are probably not
attributed to pharmacodynamic properties of the drug. By comparison, there is some
evidence that in vivo Ro15-1788 binding is decreased and that Cl− uptake by cortical
synaptoneurosomes is reduced in NC900 mice [65]. Our quantitative autoradiography results
with Ro15-4513 reveal marked reductions in DZ binding in NC900 mice in multiple brain
regions associated with the regulation of emotional responses. Affective aspects of olfaction
are mediated through direct connections between the mitral layer of the olfactory bulb and
the medial and posteromedial amygdala [15], which shape the behavioral significance of
stimuli. Parenthetically, NC900 mice do not appear to be impaired in olfactory responses
(unpublished observations). This olfactory information is relayed from the amygdala to
orbitofrontal cortex where conscious perception and identification of odors converge [2].
The lateral and basolateral amygdala represent a central hub where a wide-range of emotion-
related processes are integrated with other brain areas (e.g., hippocampus and frontal cortex)
[35] through an extensive network of GABAergic neurons [10]. The basolateral amygdala
has extensive connections with the central nucleus [57] which sends projections to lateral
hypothalamic and brainstem regions to control the autonomic functions. Projections are sent
also to the hypothalamic paraventricular nucleus to control pituitary stress responses and to
the periaqueductal gray in brainstem to control defensive behaviors [21]. With the
exceptions of the central amygdala and lateral hypothalamus, NC900 mice possess reduced
DZ-sensitive binding in all these sites. A loss of GABAA receptor-mediated inhibition in
circuits controlling emotional responses may enhance excitatory drive in emotion pathways
that detect, process, and generate defensive responses to threat. Hence, hyper-excitability of
these circuits may render NC900 mice more sensitive to anxiety- and aggression-producing
stimuli than NC100 animals.
4.4. The α2 subunit protein of the GABAA receptor is reduced in NC900 mice
The pharmacological action of DZ is determined by the subunit composition and expression
of the GABAA receptor subunits [48]. The benzodiazepine receptor is commonly composed
of pentamers of the α, β, and γ subunits [59], where the α and γ subunits form the
benzodiazepine binding site [8]. Benzodiazepine receptors containing the α1, α2, α3, and/or
α5 subunits and the γ2 subunit are sensitive to this drug [7,30], and they determine the
pharmacologic properties of classical benzodiazepines like DZ. A single histidine residue in
the α1, α2, α3, and/or α5 subunits renders these GABAA receptors responsive to
benzodiazepines and replacement of this residue with arginine makes them insensitive to DZ
[7,37]. For example, α1 H101R knockin mice fail to show sedative and amnesic responses
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to DZ, while anticonvulsant actions of DZ are partially retained [41,55]. Importantly, these
mutants retain the anxiolytic-like, motor-impairing, and myorelaxant effects of DZ. By
comparison, α2 H101R knockin animals are insensitive to DZ anxiolytic actions, whereas
α3 H101R and α5 H101R knockin mice respond to DZ in the light-dark box and elevated
plus maze [37,55]. Since DZ does not affect motor or anxiety-like behaviors in α3 or α5
H101R knockin mice [56], levels of the α1 and α2 subunit proteins were quantified in
amygdala and frontal cortex -- two brain areas well-known to mediate anxiety [20]. The γ2
subunit was examined also because this subunit is required to form the benzodiazepine
binding-pocket and γ2 heterozygotes display enhanced anxiety that can be reversed with DZ
[18]. Although levels of α1, α2, or γ2 mRNAs were similar in the NC lines, some changes
in protein concentrations were observed. While levels of α1 and γ2 subunit proteins were
indistinguishable by mouse line, concentrations of the α2 subunit protein were decreased at
least in frontal cortex and amygdala of NC900 mice. These mRNA and protein results
indicate that synthesis and/or degradation of the α2 subunit protein may be altered in NC900
animals. The selective reduction of the α2 subunit protein in NC900 animals and their
abnormal responses to DZ in the zero maze and dyadic social tests suggests that heightened
anxiety and aggression may be controlled through changes in the levels of this GABAA
receptor subunit. Additionally, since it has been estimated that up to 15% of all DZ-sensitive
GABAA receptors possess the α2 subunit [39] and because this protein is expressed
primarily in limbic areas, cerebral cortex, and striatum, our results indicate that anxiety and
reactive aggression of NC900 mice may be controlled by these brain regions.
4.5. DZ reduces reactivity and attack behaviors in NC900 mice
Compared to NC100 mice, NC900 males demonstrated higher rates of SR and LR along
with TP and attack responses. These findings replicate those previously reported in these
lines of selectively bred mice [16,27,28,32,65]. For the first time, we also report that NC900
males are less likely to engage in more intense forms of social investigation (ISI), whereas
the overall durations of milder forms of investigation (MSI) are similar those of NC100
males. Additionally, we show that the social responses of the C3H partners are dependent
upon the social behaviors displayed by the NC900 target mice. Detailed analyses of
individual behaviors that comprise the six domains of social behavior by both target and
partner mice suggest that NC900 males may be executing defensive rather than offensive
agonistic responses. This idea is supported by the observation that NC900 males rarely
initiate approaches towards the unfamiliar C3H partner and show increased instances of
defensive boxing, reactive vocalizations, and kicking. Moreover, instead of withdrawing
from the novel social stimulus, NC900 males instigate agonistic responses characterized by
feints, bites and attacks. The increased incidences of bites relative to attacks and feints
indicate that NC900 males engage in agonistic responses that require only brief contact with
the C3H partner, suggestive of responses that reflect the heightened social reactivity and
anxiety of the NC900 males in novel contexts. Taken together, the current findings provide
strong evidence that NC900 males view the mild social repertoire of the C3H partner as
threatening and they react to this situation by engaging in defensive agonistic responses.
Since the NC900 males display anxiety-like behaviors and because DZ is known to reduce
anxiety-like responses in rodents [46,58,65], effects of this benzodiazepine on social
behavior were examined in NC900 mice. It should be emphasized that effects of
benzodiazepines on social behavior are controversial, in that they have been reported to
exert anti-aggressive effects [49], as well as, disinhibit aggression in humans and animals
[23,42]. One problem in studies where anti-aggressive influences are found is that the effects
may be observed at doses that elicit neuromuscular impairment. In the present studies, we
selected doses of DZ that were below the myorelaxant effects on the wire-hang test for
NC900 mice. In our hands, DZ clearly reduced behavioral reactivity and attack behaviors in
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NC900 mice while increasing approach behaviors. As the dose of DZ increased, sniffing
was replaced by the more intense nosing behavior in NC900 males. Simultaneously, SR was
reduced in NC900 animals with decreases in defensive boxing, vocalizations, and kicking
behaviors. DZ dose-dependently increased TP by NC900 males, while attack and biting
behaviors decreased -- suggesting that DZ shifted NC900 social responses to less intense
agonistic behaviors. The reductions in bites, as feints and climb-grooming became more
prevalent, suggests that DZ shifted responses of NC900 mice to behaviors that require
sustained contact with their partners. These data not only support a previous hypothesis that
aggression in the NC900 animals reflects fight-flight responses [51], but they also indicate
that the aggression in these males is defensive in nature. This is intriguing since it has been
reported that the fight-flight responses generate different defensive behaviors depending
upon perceptual inputs and the regulation of anxiety and emotional responses [22]. The DZ-
induced shift in NC900 social responses is also consistent with Blanchard and colleague’s
[9] interpretation of benzodiazepine effects on rodent defensive behaviors where they found
these drugs produced a shift in defensive responses from higher to lower intensities. Our
results provide support for this model and suggest this behavioral effect is likely mediated
by the ability of benzodiazepines to reduce excitatory activity in the brain circuitry
subserving anxiety and/or emotionality. The ability of DZ to attenuate rapid attack and
defensive reactivity-related behaviors in NC900 mice suggests that anxiety promotes the
reactivity and rapid attack in these animals. However, because anxiety-like and aggressive
behaviors were differentially responsive to the various doses of DZ, these behaviors may
rely upon interacting and/or separate mechanisms for their full expression.
4.6. Co-morbidities of anxiety and aggression in NC900 mice
The co-appearance of high anxiety and high aggression within the same organism is unusual
and may seem paradoxical. Human anxiety disorders are often characterized by avoidance,
not aggressive behavior [1]. As a result, many animal models of anxiety use avoidance as a
means to identify anxiety-like responses [19]. Nevertheless, anxiety and aggression are co-
expressed in mice [24] and they can be co-morbid in humans with borderline personality
disorder [36,60] and posttraumatic stress disorder [5,6,40]. Both human conditions are
associated with reactive, impulsive aggression, and this behavior is thought to be due to
hyperarousal of threat detection systems [44] and may be caused by reductions in
benzodiazepine receptors [12]. Since avoidance and aggressive behaviors are defensive
responses that involve negative affective, hyper-vigilant, and attentional biases towards
sources of threat [4,21], avoidance and aggression may share similar neural substrates when
regulation of emotion is impaired.
As high and low aggression are reliably elicited in NC900 and NC100 animals, respectively,
these mouse lines are uniquely suited to evaluate the contributions of genetic and
environmental factors to the development and expression not only of aggression, but also of
anxiety and emotional dysregulation. From our findings it is tempting to speculate that
selection for high- and low-aggression in the NC mouse lines also involved concurrent
selection for high and low reactivity through changes in DZ-sensitive GABAergic
mechanisms in emotion-related brain areas. According to this scheme, selection for high
aggression involved concomitant selection for hyper-responsiveness to conspecific social
stimuli as mediated by hyperexcitable emotional brain substrates -- mechanisms similar to
those thought to underlie human aggression [21]. While NC line differences in DZ-sensitive
GABAA receptor binding and α2 subunit protein expression may reflect differential
regulation of benzodiazepine receptor subunit composition, changes in GABAergic function
may also affect responses in other neurotransmitter systems. Within this context, it will be
important in the future to evaluate responses in additional transmitter systems to more fully
understand relationships between anxiety and aggression. Results from these studies may
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provide new insights into the pathogenesis and treatment of disorders that have components
of anxiety and aggression in humans.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was partially supported by a Veterans Administration (Mid-Atlantic Mental Illness Research, Education,
and Clinical Center) grant and unrestricted funds (W.C.W.), NIH training grants 2-T32-HD007376 and T32
ES007126 (D.L.N.), and NIH Center For Developmental Science grant 1 P50 MH52429 (J.-L.G., D.L.N.). We wish
to thank Drs. Jack Keene and Dhanrajan Tiruchinapalli at the Duke University Medical Center for helping with
real-time RT-PCR, Ms. Lindsey E. Phillips for her assistance in the behavioral studies, and The Separations Group,
Hisperia, CA for supplying the HPLC column for separation of DZ and its metabolites.
References
[1]. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.
American Psychiatric Association; Washington, DC: 1994. p. 429-485.
[2]. Anderson AK, Christoff K, Stappen I, Panitz D, Ghahremani DG, Glover G, Gabrieli JD, Sobel N.
Dissociated neural representations of intensity and valence in human olfaction. Nat Neurosci.
2003; 6:196–202. [PubMed: 12536208]
[3]. Bakemann, R.; Gottman, JM. Observing Interaction: An Introduction to Sequential Analysis. 2nd
ed. Cambridge University Press; Cambridge: 1997. p. 58-80.
[4]. Barlow, DH. Anxiety and its Disorders: The Nature and Treatment of Anxiety and Panic. 2nd ed.
Guilford Press; New York: 2002.
[5]. Beckham JC, Feldman ME, Kirby AC, Hertzberg MA, Moore SD. Interpersonal violence and its
correlates in Vietnam veterans with chronic posttraumatic stress disorder. J Clin Psychol. 1997;
53:859–869. [PubMed: 9403389]
[6]. Begic D, Jokic-Begic N. Aggressive behavior in combat veterans with post-traumatic stress
disorder. Mil Med. 2001; 166:671–676. [PubMed: 11515314]
[7]. Benson JA, Löw K, Keist R, Möhler H, Rudolph U. Pharmacology of recombinant γ-
aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated α-subunits. FEBS
Lett. 1998; 431:400–404. [PubMed: 9714551]
[8]. Berezhnoy D, Nyfeler Y, Gonthier A, Schwob H, Goeldner M, Sigel E. On the benzodiazepine
binding pocket in GABAA receptors. J Biol Chem. 2004; 279:3160–3168. [PubMed: 14612433]
[9]. Blanchard DC, Griebel G, Rodgers RJ, Blanchard RJ. Benzodiazepine and serotonergic
modulation of antipredator and conspecific defense. Neurosci Biobehav Rev. 1998; 22:597–612.
[PubMed: 9662722]
[10]. Bowery N, Hudson A, Price G. GABAA and GABAB receptor site distribution in the rat central
nervous system. Neuroscience. 1987; 20:365–383. [PubMed: 3035421]
[11]. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of
protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–254.
[PubMed: 942051]
[12]. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased
benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress
disorder. Am J Psychiatry. 2000; 157:1120–1126. [PubMed: 10873921]
[13]. Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E,
Cappiello A, Woods S, Baldwin R, Charney DS. SPECT [I-123]iomazenil measurement of the
benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000; 47:96–106. [PubMed:
10664825]
[14]. Bućan M, Abel T. The mouse: genetics meets behaviour. Nat Rev Genet. 2002; 3:114–123.
[PubMed: 11836505]
Nehrenberg et al. Page 16













[15]. Buck LB. Information coding in the vertebrate olfactory system. Annu Rev Neurosci. 1996;
19:517–544. [PubMed: 8833453]
[16]. Cairns RB, MacCombie DJ, Hood KE. A developmental-genetic analysis of aggressive behavior
in mice: I. Behavioral outcomes. J Comp Psychol. 1983; 97:69–89. [PubMed: 6603330]
[17]. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic
effects of benzodiazepines. Pharmacol Biochem Behav. 1980; 13:167–170. [PubMed: 6106204]
[18]. Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent JP, Belzung C, Fritschy JM, Luscher
B, Möhler H. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for
threat cues. Nat Neurosci. 1999; 2:833–839. [PubMed: 10461223]
[19]. Cryan JF, Holmes A. Model organisms: The ascent of mouse: advances in modelling human
depression and anxiety. Nat Rev Drug Discov. 2005; 4:775–790. [PubMed: 16138108]
[20]. Davidson RJ. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol
Psychiatry. 2002; 51:68–80. [PubMed: 11801232]
[21]. Davidson RJ, Putnam KM, Larson CL. Dysfunction in the neural circuitry of emotion regulation
-- a possible prelude to violence. Science. 2000; 289:591–594. [PubMed: 10915615]
[22]. Derryberry, D.; Reed, MA. Information processing approaches to individual differences in
emotional reactivity. In: Davidson, RJ.; Scherer, KR.; Goldsmith, HH., editors. Handbook of
Affective Sciences. Oxford University Press; New York: 1998. p. 681-697.
[23]. DiMascio A. The effects of benzodiazepines on aggression: reduced or increased?
Psychopharmacologia. 1973; 30:95–102. [PubMed: 4576033]
[24]. Ferrari PF, Palanza P, Parmigiani S, Rodgers RJ. Interindividual variability in Swiss male mice:
relationship between social factors, aggression, and anxiety. Physiol Behav. 1998; 63:821–827.
[PubMed: 9618005]
[25]. Fuchs, E.; Flugge, G. Animal models of anxiety disorders. In: Charney, DS.; Nesler, EJ., editors.
Neurobiology of Mental Illness. 2nd ed. Oxford University Press; New York: 2004. p. 546-557.
[26]. Fukui M, Rodriguiz RM, Zhou J, Jiang SX, Phillips LE, Caron MG, Wetsel WC. Vmat2
heterozygous mutant mice display a depressive-like phenotype. J Neurosci. 2007; 27:10520–
10529. [PubMed: 17898223]
[27]. Gariépy JL, Gendreau PL, Cairns RB, Lewis MH. D1 dopamine receptors and the reversal of
isolation-induced behaviors in mice. Behav Brain Res. 1998; 95:103–111. [PubMed: 9754882]
[28]. Gariépy JL, Hood KE, Cairns RB. A developmental-genetic analysis of aggressive behavior in
mice (Mus musculus): III. Behavioral mediation by heightened reactivity or immobility? J Comp
Psychol. 1988; 102:392–399. [PubMed: 3215014]
[29]. Gendreau PL, Gariépy JL, Petitto JM, Lewis MH. D1 dopamine receptor mediation of social and
nonsocial emotional reactivity in mice: effects of housing and strain difference in motor activity.
Behav Neurosci. 1997; 111:424–434. [PubMed: 9106681]
[30]. Günther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Crestani F, Aguzzi A,
Arigoni M, Lang Y, Bluethmann H, Möhler H, Lüscher B. Benzodiazepine-insensitive mice
generated by targeted disruption of the γ2 subunit gene of α-aminobutyric acid type A receptors.
Proc Natl Acad Sci USA. 1995; 92:7749–7753. [PubMed: 7644489]
[31]. Henn FA, Vollmayr B. Stress models of depression: forming genetically vulnerable strains.
Neurosci Biobehav Rev. 2005; 29:799–804. [PubMed: 15925700]
[32]. Hood KE, Quigley KS. Exploratory behavior in mice selectively bred for developmental
differences in aggressive behavior. Develop Psychobiol. 2009; 50:32–47.
[33]. Korpi ER, Kleingoor C, Kettenmann H, Seeburg PH. Benzodiazepine-induced motor impairment
linked to point mutation in cerebellar GABAA receptor. Nature. 1993; 361:356–359. [PubMed:
7678923]
[34]. Kosel M, Rudolph U, Wielepp P, Luginbühl M, Schmitt W, Fisch HU, Schlaepfer TE.
Diminished GABAA receptor-binding capacity and a DNA base substitution in a patient with
treatment-resistant depression and anxiety. Neuropsychopharmacology. 2004; 29:347–350.
[PubMed: 14628001]
[35]. LeDoux, J. The Emotional Brain. Simon & Schuster; New York: 1996.
[36]. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder.
Lancet. 2004; 364:453–461. [PubMed: 15288745]
Nehrenberg et al. Page 17













[37]. Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann
H, Möhler H, Rudolph U. Molecular and neuronal substrate for the selective attenuation of
anxiety. Science. 2000; 290:131–134. [PubMed: 11021797]
[38]. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABAA-
benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET
study. Arch Gen Psychiatry. 1998; 55:715–720. [PubMed: 9707382]
[39]. Marksitzer R, Benke D, Fritschy JM, Trzeciak A, Bannwarth W, Möhler H. GABAA-receptors:
drug binding profile and distribution of receptors containing the α2-subunit in situ. J Recept Res.
1993; 13:467–477. [PubMed: 8383760]
[40]. McFall M, Fontana A, Raskind M, Rosenheck R. Analysis of violent behavior in Vietnam
combat veteran psychiatric inpatients with posttraumatic stress disorder. J Trauma Stress. 1999;
12:501–517. [PubMed: 10467558]
[41]. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J,
Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore
KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ. Sedative but not
anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype.
Nature Neurosci. 2000; 3:587–592. [PubMed: 10816315]
[42]. Miczek KA, Fish EW, De Bold JF, De Almeida RM. Social and neural determinants of
aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric
acid systems. Psychopharmacology (Berl). 2002; 163:434–458. [PubMed: 12373445]
[43]. Nutt DJ, Malizia AL. Structural and functional brain changes in posttraumatic stress disorder. J
Clin Psychiatry. 2004; 65(Suppl 1):11–17. [PubMed: 14728092]
[44]. Pavic L, Gregurek R, Petrovic R, Petrovic D, Varda R, Vukusic H, Crnkovic-Markovic S.
Alterations in brain activation in posttraumatic stress disorder patients with severe hyperarousal
symptoms and impulsive aggressiveness. Eur Arch Psychiatry Clin Neurosci. 2003; 253:80–83.
[PubMed: 12799745]
[45]. Paxinos, G.; Franklin, K. The Mouse Brain in Stereotaxic Coordinates. 2nd ed. Academic Press;
London: 2001.
[46]. Pogorelov VM, Rodriguiz RM, Insco ML, Caron MG, Wetsel WC. Novelty-seeking and
stereotypic activation of behavior in mice with disruption of the Dat1 gene.
Neuropsychopharmacology. 2005; 30:1772.
[47]. Potokar J, Coupland N, Wilson S, Rich A, Nutt D. Assessment of GABAA benzodiazepine
receptor (GBzR) sensitivity in patients on benzodiazepines. Psychopharmacology (Berl). 1999;
146:180–184. [PubMed: 10525753]
[48]. Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofield PR, Seeburg PH.
Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature. 1989;
338:582–585. [PubMed: 2538761]
[49]. Randall, LO.; Schallek, W. Pharmacological activity of certain benzodiazepines. In: Effron, DH.,
editor. Psychopharmacology. Public Health Service Publication; 1968. p. 153-184.
[50]. Rodriguiz RM, Chu R, Caron MG, Wetsel WC. Aberrant responses in social interaction of
dopamine transporter knockout mice. Behav Brain Res. 2004; 148:185–198. [PubMed:
14684259]
[51]. Rodriguiz, RM.; Jones, BC.; Gariepy, JL. Biobehavioral modes of adaptation in mice selectively
bred for aggression: characterization, plasticity, and malleability. In: Hahn, D., editor. Advancing
Research on Developmental Plasticity. NIMH; Rockville MD: 1998. p. 271-273.
[52]. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE. Behavioral and functional
analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype
assessment. Mamm Genome. 1997; 8:711–713. [PubMed: 9321461]
[53]. Roy-Byrne P, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. Reduced benzodiazepine
sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive
disorder and normal subjects. Am J Psychiatry. 1996; 153:1444–1449. [PubMed: 8890678]
[54]. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D. Reduced benzodiazepine
sensitivity in panic disorder. Arch Gen Psychiatry. 1990; 47:534–538. [PubMed: 2161643]
Nehrenberg et al. Page 18













[55]. Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H,
Möhler H. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes.
Nature. 1999; 401:796–800. [PubMed: 10548105]
[56]. Rudolph U, Möhler H. Analysis of GABAA receptor function and dissection of the
pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev
Pharmacol Toxicol. 2004; 44:475–498. [PubMed: 14744255]
[57]. Sah P, Faber ES, Lopez De Armentia M, Power J. The amygdaloid complex: anatomy and
physiology. Physiol Rev. 2003; 83:803–834. [PubMed: 12843409]
[58]. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological
characterization of the elevated “zero-maze” as an animal model of anxiety.
Psychopharmacology (Berl). 1994; 116:56–64. [PubMed: 7862931]
[59]. Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Höger H, Adamiker D. Structure and
subunit composition of GABAA receptors. Neurochem Int. 1999; 34:379–385. [PubMed:
10397365]
[60]. Skodol AE, Gunderson JG, Pfohl B, Widiger TA, Livesley WJ, Siever LJ. The borderline
diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry. 2002;
51:936–950. [PubMed: 12062877]
[61]. St-Pierre MV, Pang KS. Concentration-dependent metabolism of diazepam in mouse liver. J
Pharmacokinet Biopharm. 1995; 23:243–266. [PubMed: 8834195]
[62]. Tiihonen J, Kuikka J, Räsänen P, Lepola U, Koponen H, Liuska A, Lehmusvaara A, Vainio P,
Könönen M, Bergström K, Yu M, Kinnunen I, Åkerman K, Karhu J. Cerebral benzodiazepine
receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol
Psychiatry. 1997; 2:463–471. [PubMed: 9399689]
[63]. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev.
1985; 9:203–222. [PubMed: 2861589]
[64]. Treit D, Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem
Behav. 1988; 31:959–962. [PubMed: 3252289]
[65]. Weerts EM, Miller LG, Hood KE, Miczek KA. Increased GABAA-dependent chloride uptake in
mice selectively bred for low aggressive behavior. Psychopharmacology. 1992; 108:196–204.
[PubMed: 1329132]
Nehrenberg et al. Page 19














Anxiety-like behaviors of NC100 and NC900 mice in the zero maze and response to DZ.
Animals were given vehicle or 0.0625, 0.125, 0.25, or 0.5 mg/kg DZ (i.p.) and tested 30 min
later. (A) Percent time in the open areas of the zero maze. (B) Latency to enter the open
areas of the maze. (C) Closed to open to closed area transitions. N = 9 mice/line/dose.
*p<0.05, NC100 versus NC900 animals; +p<0.05, NC100 mice: vehicle versus DZ;
#p<0.05, NC900 mice: vehicle versus DZ.
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Differential myorelaxant and motor-impairing effects of DZ in NC100 and NC900 mice.
Animals were pre-trained for 2 days on the rotorod and wire-hang tests, and evaluated with
vehicle, 1, 2, 5, or 10 mg/kg DZ (i.p.) 30 min after injection. (A) Latency to grasp the wire.
(B) Duration of wire hang. (C) Latencies to fall from the rotorod. N = 9-16 mice/line/dose.
(D) Deficits in the contact righting reflex. *p<0.05, NC100 versus NC900 animals; +p<0.05,
NC100 mice: vehicle-controls versus DZ; #p<0.05, NC900 mice: vehicle-controls versus
DZ.
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Representative autoradiographic distribution of DZ-sensitive binding in coronal sections
from NC100 and NC900 brains. (A) Binding in the frontal cortex and mitral layer of the
olfactory bulb at ~2.68 mm bregma [47]. (B) Binding in areas 1-2 of cingulate cortex and
bed nucleus of stria terminalis at ~0.26 bregma. (C) Binding in lateral amygdala at ~1.34
bregma. (D) Binding in somatosensory cortex, lateral amygdala, and ventromedial
hypothalamus at ~-1.58 bregma. (E) Binding in CA1 and CA3 hippocampus, dentate gyrus,
paraventricular thalamus, lateral amygdala, basolateral amygdala, and medial amygdaloid
nucleus at ~-1.82 bregma. (F) Binding in CA1 hippocampus, dentate gyrus, periaqueductal
gray, and posterior cortical amygdala at ~-3.52 bregma. (G) Binding in the central nucleus
of the inferior colliculus and locus coerulus at ~-5.34 bregma. (H) Binding in the central
lobule of the cerebellum and nucleus of the solitary tract at ~-6.96 bregma. The values are
expressed in μCi/g and represent DZ-sensitive binding where N = 6 mice/line. Scale bar = 1
mm. *p<0.05, NC100 versus NC900 mice.
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Western-blot of GABAA receptor α1, α2, and γ2 subunits. (A) Western blot (5 μg/lane) of
brain samples with primary (Ab) or pre-absorbed antisera (Ab-Ag) demonstrating specificity
of the α1, α2, γ2, and β-actin antisera; immunoreactive bands are shown at approximately
49, 59, 49, and 44 kiloDaltons (kDa), respectively. (B) Representative immunoreactive
bands with increasing amounts of total protein (2.5, 5, and 10 μg), together with
quantification of intensities of α1, α2, and γ2 immunoreactivities in frontal cortex (left) and
amygdala (right) from NC100 (open circles) and NC900 mice (filled circles).
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Effects of DZ on social behaviors of NC900 males in a dyadic test. C3H partner males and
NC100 animals were untreated. (A) Mild social investigation (MSI). (B) Intensive social
investigation (ISI). (C) Stationary reactivity (SR). (D) Locomotor reactivity (LR). (E)
Threatening postures (TP). (F) Attacks. N = 9-11 mice/line/dose. *p<0.05, NC100 vehicle-
controls versus NC900 vehicle-controls; #p<0.05, behaviors of NC900 vehicle controls
versus 0.5, 1, or 1.5 mg/kg DZ or for C3H partner mice paired to NC900 vehicle controls
versus C3H partner mice paired to NC900 males treated with 0.5, 1 or 1.5 mg/kg DZ;
+p<0.05, NC900 animals treated with 0.5 mg/kg DZ compared to NC900 males treated with
1 or 1.5 mg/kg DZ, or C3H partner mice paired to NC900 animals given 0.5 mg/kg DZ
compared to C3H partner mice paired to NC900 males given 1 or 1.5 mg/kg DZ; ‡p<0.05,
NC900 mice treated with 1.5 mg/kg DZ compared to NC900 males treated with 0.5 or 1 mg/
kg DZ, or C3H partner mice paired to NC900 animals given 1.5 mg/kg DZ compared to
C3H partner mice paired to NC900 males given 0.5 or 1 mg/kg DZ; p<0.05, C3H partners
paired with NC100 males versus C3H partners paired with NC900 males; ^p<0.05, NC900
target mice versus its C3H partners.
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Table 1
Immobility to social contact in NC100 and NC900 animals
Behavior Groupa Response
Freezing (% time) NC100 – Vehicle 38.6 ± 1.6
NC900 - Vehicle 0.2 ± 0.2b
NC900 – 0.5 mg/kg DZ 0.5 ± 0.3
NC900 – 1 mg/kg DZ 1.1 ± 0.7
NC900 – 1.5 mg/kg DZ 1.5 ± 0.8
Latency to Freeze (s) NC100 – Vehicle 28.6 ± 3.7
NC900 - Vehicle 204.6 ± 26.4c
NC900 – 0.5 mg/kg DZ 190.3 ± 33.4
NC900 – 1 mg/kg DZ 187.6 ± 24.8
NC900 – 1.5 mg/kg DZ 212.2 ± 19.5
a
N = 9-11 mice/line.
b
T-test for NC100 and NC900 mice administered vehicle [t1,18 = 25.041, p<0.001].
c
T-test for vehicle-treated NC100 and NC900 mice [t1,18 = 15.958, p<0.001].
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Table 2
Latencies to engage in social behaviors by NC100 and NC900 mice
Domain Groupa Latency (s)
MSI NC100 – Vehicle 6.1 ± 1.3
NC900 - Vehicle 15.3 ± 2.3b
NC900 – 0.5 mg/kg DZ 4.8 ± 0.7c
NC900 – 1 mg/kg DZ 3.1 ± 0.4c
NC900 – 1.5 mg/kg DZ 5.2 ± 0.9c
ISI NC100 – Vehicle 21.9 ± 4.7
NC900 - Vehicle 123.8 ± 30.4d
NC900 – 0.5 mg/kg DZ 208.1 ± 24.9e
NC900 – 1 mg/kg DZ 191.4 ± 14.1e
NC900 – 1.5 mg/kg DZ 238.6 ± 12.7e
SR NC100 – Vehicle 136.2 ± 26.1
NC900 - Vehicle 32.6 ± 6.8f
NC900 – 0.5 mg/kg DZ 40.5 ± 7.7
NC900 – 1 mg/kg DZ 59.9 ± 6.9g
NC900 – 1.5 mg/kg DZ 110.6 ± 9.3g
LR NC100 – Vehicle 291.3 ± 8.7
NC900 - Vehicle 59.4 ± 7.5h
NC900 – 0.5 mg/kg DZ 131.4 ± 25.7i
NC900 – 1 mg/kg DZ 246.9 ± 19.7i
NC900 – 1.5 mg/kg DZ 269.2 ±12.4i
TP NC100 – Vehicle 296.7 ± 3.2
NC900 - Vehicle 38.2 ± 7.9j
NC900 – 0.5 mg/kg DZ 33.4 ± 3.8
NC900 – 1 mg/kg DZ 78.3 ± 10.7k
NC900 – 1.5 mg/kg DZ 173.4 ± 24.1k
Attacks NC100 – Vehicle 300.0 ± 0.0
NC900 - Vehicle 101.5 ± 11.6l
NC900 – 0.5 mg/kg DZ 97.9 ± 16.5
NC900 – 1 mg/kg DZ 149.6 ± 35.2m
NC900 – 1.5 mg/kg DZ 244.9 ± 17.3m
a
N = 9-11 mice/line/dose.
b
T-test for vehicle-treated NC100 and NC900 mice [t1,18 = 3.258, p<0.004].
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c
ANOVA for NC900 animals given DZ [F3,36 = 15.575, p<0.001]; vehicle versus 0.5 mg/kg (p<0.001); vehicle versus 1 mg/kg (p<0.001); vehicle
versus 1.5 mg/kg (p<0.001).
d
T-test for NC100 and NC900 mice given vehicle [t1,18 = 2.988, p<0.008].
e
ANOVA for DZ-treated NC900 animals [F3,36 = 8.243, p<0.001]; vehicle versus 0.5 mg/kg (p<0.004); vehicle versus 1 mg/kg (p<0.003);
vehicle versus 1.5 mg/kg (p<0.001).
f
T-test for NC100 and NC900 mice administered vehicle [t1,18 = 4.189, p<0.001].
g
ANOVA for NC900 animals given DZ [F3,36 = 20.471, p<0.001]; vehicle versus 1 mg/kg (p<0.006); vehicle versus 1.5 mg/kg (p<0.001).
h
T-test for vehicle-treated NC100 and NC900 mice [t1,18 = 20.279, p<0.001].
i
ANOVA for NC900 animals administered DZ [F3,36 = 31.462, p<0.001]; vehicle versus 0.5 mg/kg (p<0.035); vehicle versus 1 mg/kg (p<0.001);
vehicle versus 1.5 mg/kg (p<0.001).
j
T-test for NC100 and NC900 mice given vehicle [t1,18 = 27.889, p<0.001].
k
ANOVA for DZ-treated NC900 animals [F3,36 = 10.920, p<0.001]; vehicle versus 1 mg/kg (p<0.030); vehicle versus 1.5 mg/kg (p<0.001).
l
T-test for NC100 and NC900 mice administered vehicle [t1,18 = 15.357, p<0.001].
m
ANOVA for NC900 animals given DZ [F3,36 = 11.931, p<0.001]; vehicle versus 1 mg/kg (p<0.033); vehicle versus 1.5 mg/kg (p<0.001).
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